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Sarcoido5is may involve virtually any organ system
and its initial manifestations are protean. Dermatologic
manifestations of sarcoidosis first cause patients to seek
medical attention in approximately 10% of cases,' and
at least 50% of patients with sarcoidosis v^ho are initially
evaluated lor dermatologic complaints either have
pulmonary disease at the time of presentation or sub-
sequently go on to develop pulmonary sarcoidosis.^
Pulmonary disease accounts for a large portion of the
morbidity and mortaiity caused by sarcoidosis. It is im-
portant that pulmonary involvement be recognized
and treated prior to the development of extensive
irreversible lung damage. Since the dermatologist may
be the first physician to evaluate a patient with sar-
coidosis and may be the patient's primary care physi-
cian, it is important that he have a clear understanding of
pulmonary sarcoidosis. This review summarizes the
manifestations of pulmonary sarcoidosis and provides
guidelines for its evaluation and treatment.
Relationship of Pulmonary and Dermatologic
Manifestations of Sarcoidosis
The prevalence of dermatologic abnormalities re-
ported in patients with sarcoidosis has varied from series
to series as seen in Table 1.^"** Erythema nodosum has
been found in recent series in as few as 3% and as many
as 31% of cases, and it appears to be much more fre-
quent in Europe than in North America. Other skin man-
ifestations including plaques, macutopapular eruptions,
subcutaneous nodules, and lupus pernio occur in 13%
to 39% of patients. More than 90% of patients with ery-
thema nodosum and approximately 70% of patients with
other skin manifestations also have pulmonary
sarcoidosis.'
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The dermatologic and pulmonary manifestations of
sarcoidosis generally follow a parallel course. Patients
who present with bilateral hilar adenopathy and ery-
thema nodosum virtually always experience clearing of
both the skin and intrathoracic disease in six months to
one year. Patients with other dermatologic manifesta-
tions, however, tend to have a chronic indolent course
with gradually progressing lung damage. Only 20% of
patients with skin lesions other than erythema nodosum
experience complete clearing of their chest roentgeno-
gram and clearing rarely occurs in the presence of lupus
pernio.**
Symptoms and Signs of Pulmonary Sarcoidosis
Pulmonary sarcoidosis is frequently asymptomatic
and may be brought to attention because of an abnormal
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FK;. 1. (A) CheM roenigenogrdm typiCiii of stage I sarcoidosib
showing hilaterial hiiar adenopatfiy wjlh clear lung fields. (Bl Chest
roentgenogram typical of stage II sarcoidosis showing both hiiar
adenopathy and bilateral pulmonary infiltrates. (C) Chest roentgeno-
gram typiciil of stage III sarroidosis showing bilateral pulmonary infil-
trates without hiiar adenopathy.
routine chest roentgenogram. When symptoms occur
they include dyspnea, cough, chest pain, and hemop-
tysis. Approximately 35% of patients with sarcoidosis
experience dyspnea at some time in the course of their
disease, 35% experience cough, 15 to 20% complain of
chest pain, and iess than 5% experience hemoptysis.
Hoarseness occurs in approximately 2% of patients and
is a manifestation of laryngeal involvement. Rarely
laryngeai sarcoidosis may lead to stridor and high grade
upper airway obstruction.
Examination of the lungs is also frequently normal in
patients with sarcoidosis even in the presence of ad-
vanced parenchymal lung disease. Bower studied 69 pa-
tients with intrathoracic sarcoidosis and found only 17
(25%) in whom rales, rhonchi, or wheezes could be
detected.^ The reason for this paucity of physical find-
ings is unknown, but significant pulmonary disease is
frequently present despite a nornial lung examination.
Chest Roentgenogram in Sarcoidosis
Since symptoms and physical findings are not sensi-
tive indicators of the presence of pulmonary sarcoidosis,
the chest roentgenogram is an extremely important part
of the pulmonary evaluation, it can be expected to be
abnormal in slightly more than 90% of patients with
sarcoidosis. Abnormal findings consist of some combi-
nation of intrathoracic adenopathy and pulmonary
parenchymal infiltrates and can be classified according
to the stage of involvement (Fig. 1).''
Roentgenographic stage I disease is characterized by
the presence of bilateral hiiar adenopathy without
pulmonary parenchymal infiltrates. Patients with stage I
disease are usually asymptomatic, though as many as
10% may experience a significant feeling of breathless-
ness. Spontaneous resolution of sarcoidosis occurs in
85% of patients with stage I disease. Stage ii disease is
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characterized by the presence of both hilar adenopathy
and puimonary parenchymal infiltrates. Patients in this
stage are more frequently symptomatic than stage I pa-
tients and have a siightly worse prognosis. Approxi-
mately 60% experience spontaneous ciearing of their
chest roentgenogram while the remainder have chronic
persistent disease. Patients with stage ill disease have
parenchymal infiltrates without hilar adenopathy. They
have the most symptoms, the greatest functional impair-
ment, and the worst prognosis. Only 20% of these pa-
tients ever experience ciearing of their chest roentgeno-
gram and many have significant pulmonary disability.
It should also be recognized that significant
pulmonary parenchymal sarcoidosis may be present
even in the [presence of a completely normal chest
roentgenogram. This pulmonary involvement can be
demonstrated either by puimonary function testing or by
lung biopsy. Epler and colleagues, for instance, reported
62 patients with biopsy confirmed pulmonary sar-
coidosis among whom 5% had completeiy normal chest
roentgenograms.'^ Pleural effusions are uncommon in
patients with sarcoidosis and occur in 1% to 2% of
cases." The fluid is exudative and may be either unilat-
eral or bilateral. Calcification of hilar nodes and pul-
monary parenchyma may occur in patients with long-
standing disease.
Pulmonary Function Tests in Sarcoidosis
Abnormalities of pulmonary function tests in patients
with sarcoidosis are not well correlated with abnor-
malities on chest roentgenogram.'^ Substantial abnor-
malities are often present in patients without
roentgenographic evidence of parenchymal lung dis-
ease. Conversely, patients with diffuse parenchymal in-
filtrates may have littie in the way of functionai impair-
ment. The reason for this poor correlation is not known
but may be related to the relative proportion of
granuiomas present in the interstitium, the pulmonary
vessels, and the airways.
Pulmonary function abnormalities that occur in pa-
tients with sarcoidosis include decrements in total lung
capacity, decreases in expiratory flow rates, and im-
pairment of gas exchange. These alterations may exist
independently or may be found together. Their severity
is variabie and they may cause no symptoms or may
resuit in significant exercise iimitation.
One of the most common abnormalities found on
routine pulmonary function tests in patients with sar-
coidosis is a decreased diffusing capacity for carbon
monoxide (D/.CO). The D^CO is frequently diminished
even in stage I disease.'̂  Measured decreases are be-
iieved to occur predominantly because of compromise
of the pulmonary capiliary bed by granulomatous in-
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i-\c,. 1. The continuous line represents a normal maximal flow-
volume curve in a patient with sarcoidosis. The dotted line depicts the
maximal flow-volume curve of the same patient after the development
of upper airway obstruction due to laryngeal sarcoidosis. Total lung
capacity is at 0% of the vital capacity and residual volume is at 100%.
Expiratory flow rates are shown above the abscissa and inspiratory
flow rates are shov̂ -n belov f̂. Expiratory flow rates are decreased during
the lirsl half of the forced vital capacity maneuver while inspiratory
rates are more symmetrically decreased.
flammation with a resulting decrease in the area of the
lung's diffusing surface.
Reductions in total lung capacity are found in more
advanced disease. It is believed to result from
granulomatous inflammation in the lung interstitium,
which decreases the compliance of the lungs and even-
tually causes obiiteration of alveoiar air spaces. Both of
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TABLE 2. Evalualion of Pulmonary Sarcoidosis
1. All patients:
a. History of respiratory symptoms;
b. Physical examination of Ihe lungs;
c. Chest roentgenogram; and
d. Pulmonary function tests:
(1) Spirometry including a maximal flow volume curve;
(2) Totai lung capacity; and
(3) Diffusing capacity for carbon monoxide
2. Selected patients:
a Arterial blood gas tension at rest and during exercise; and
b. Fiberoptic hronchoscopy with biopsy.
these consequences of interstitial granulomas serve to
decrease the voiume of gas that the patient can inspire
and hence decrease total lung capacity.
Obstructive airways disease is also a feature of
puimonary sarcoidosis and is characterized by de-
creased expiratory airflow rates, it may be miid and only
detected by sensitive physiologic tests or may be quite
severe and result in a substantial aiteration in the pa-
tient's exercise toierance. The etiology of this obstructive
airway disease may be related to smali airway com-
promise by granuiomas or to distortion of larger airways
resulting from pulmonary fibrosis. In addition, we have
recently collected data in our laboratory which suggests
that airway granulomas cause increased airways smooth
muscle constriction in response to nonspecific airway
irritants.'^
Upper airway obstruction may also occur in patients
with sarcoidosis and is usuaiiy due to iaryngeai in-
volvement.''' Obstruction of the large airways can be
differentiated from more peripheral airways obstruction
by plotting air How against the voiume of gas expired
during a forced expiratory maneuver. Peripheral airways
obstruction-causes decreased flow rates in the last half of
the vital capacity, while obstruction of large central air-
ways produces decreased fiow rates during the first half
of the forced vital capacity maneuver. The characteristic
alteration in the flow volume curve seen in upper airway
obstruction is depicted in Fig. 2. it is of some importance
that upper airway obstruction be detected since
laryngeal sarcoidosis may cause complete upper airway
obstruction and asphyxiation.
Arterial Blood Gas Determination in Sarcoidosis
The partial pressures of oxygen (PO2) and carbon
dioxide (PCO2) in the arterial blood of patients with early
sarcoidosis are often normai. As the pulmonary paren-
chymal disease progresses, the PO2 falls. Advanced
parenchymai disease particuiariy in the presence of fi-
brotic changes may result in significant hypoxemia (PO2
< 60 mmHg) and occasionally in hypercarbia (PCO2 >
44 mmHg). Although moderate exercise usuaiiy results
in little change in arteriai blood gases, it may cause the
PO2 to fail in patients with advanced pulmonary sar-
coidosis. Measurement of arterial blood gas tensions in
patients with advanced disease may be useful in deter-
mining the need for treatment with supplemental
oxygen.
Diagnosis of Sarcoidosis
Confident diagnosis of sarcoidosis requires: (1) a clin-
ical and roentgenographic presentation consistent with
sarcoidosis; (2) biopsy demonstration of noncaseating
granulomas; and (3) exclusion by special stains and cul-
tures of specific infections causing granulomatous in-
flammation. Biopsy material can be obtained from any
organ but is most frequently obtained from si<in, lung, or
lymph nodes. Since locai "sarcoid reactions" have been
reported in neopiastic diseases, it is occasionally desira-
ble to obtain tissue from more than one source.
The recent development of fiberoptic bronchoscopy
with transbronchial iung biopsy has made lung tissue
relatively easy to obtain. One can expect to find nnn-
caseating granuiomas via transbronchoscopic biopsy in
66% of patients with stage I disease, 84% of patients
with stage II disease, and 83% of patients with stage iil
disease.'^ Endobronchial biopsies also reveal
granulomas particularly when mucosal abnormalities
are visualized.'^
The Kveim test may also be used as an aid to diag-
nosis. A positive Kveim test occurs in 70 to 90% of pa-
tients with active disease and is associated with a low
rate (1 to 2%) of false positive results.'^ It is rarely help-
ful, however, in patients with diffuse pulmonary infil-
trates without hilar adenopathy, and standardized Kveim
antigen is not readily avaiiable.
Evaluation and Treatment of Pulmonary Sarcoidosis
Patients presenting with dermatologic manifestations
of sarcoidosis should have an initial pulmonary evalua-
tion as outlined in Table 2. All patients should be ques-
tioned concerning symptoms of dyspnea, cough, chest
pain, or hemoptysis and should undergo careful physical
examination of the lungs. In addition, all patients should
have a chest roentgenogram and puimonary function
studies inciuding spirometry, determination of totai lung
capacity, and measurement of the diffusing capacity for
carbon monoxide. In selected patients in whom the
diagnosis of sarcoidosis is in question, the performance
of fiberoptic bronchoscopy with transbronchiai lung
biopsy provides a source of tissue for examination.
When serious impairment of pulmonary function exists
and administration of supplemental oxygen is being
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considered, arterial blood gases at rest and following
exercise should be obtained.
Pulmonary sarcoidosis is best treated with systemic
corticosteroids. In the majority of cases this results in
both symptomatic and physiologic improvement. Al-
though the effect of corticosteroids on long-term prog-
nosis has not been clearly established, it is likely that it
results in preservation of lung function. Not all patients
with pulmonary sarcoidosis, however, should be treated.
Treatment should be reserved for patients with dyspnea
on exertion and significantly abnormal or deteriorating
pulmonary function tests and patients with persistent
parenchymal infiltrates not resolving over a six-month
period.'-' Baseline pulmonary function tests and an initial
chest roentgenogram are thus essential for making initial
decisions concerning steroid therapy and are useful as a
reference for later comparison.
Treatment of pulmonary sarcoidosis is started with
oral prednisone in a dose of 40 mg per day. This should
be continued for four weeks, and the patient's
symptoms, chest roentgenogram, and pulmonary func-
tion studies should be evaluated again. If no improve-
ment has occurred, the prednisone is gradually discon-
tinued over the next two to three weeks. If improvement
has occurred, the dose of prednisone is decreased to 20
to 40 mg every other day. This amount is continued at
least one year prior to attempting to completely with-
draw steroid therapy.
Summary
Patients presenting with dermatologic manifestations
of sarcoidosis frequently have coexisting lung disease
and should have pulmonary evaluation including a his-
tory of pulmonary symptoms, an examination of the
lungs, a chest roentgenogram, and pulmonary function
studies. In selected cases, fiberoptic bronchoscopy and
the determination of arterial blood gas tensions may also
prove useful. The data obtained from this evaluation aids
in the decisions concerning the institution of cortico-
steroid treatment for pulmonary sarcoidosis and pro-
vides baseline information for following the course of
the disease.
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Mycosis Fungoides
Mycosis fungoides is generally regarded as a malignant T-cell lymphoma arising in skin.' Its
cutaneous manifestations range from pruritic erythematous macules through infiltrated scaly plaques
to tumours which may ulcerate and become infected. In advanced disease the lymph-nodes, liver,
and spleen may become involved, and the outcome is then usually fatal. It is generally accepted that
advanced mycosis fungoides is resistant to treatment, but there is disagreement about the manage-
ment of the disease in its early stages when it is confined to the skin. Early and aggressive therapy with
curative intent is advocated by some, but many centres favour a conservative and essentially
symptomatic approach to treatment. Photochemotherapy (PUVA) has been reported to be of benefit in
the treatment of mycosis fungoides.̂ "** The mode of action is thought to be related to inhibition of
DNA synthesis and mitosis in the T lymphocytes in the cutaneous infiltrate.—Briffa DV, Warin AP,
Harrington, Cl, et al: Photochemotherapy in mycosis fungoides. Lancet i:49, 1980

